Chronic HCV Infection Clinical Trial
Official title:
A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection
This study will evaluate the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) tablet with or without ribavirin (RBV) in treatment-naive or treatment-experienced Japanese participants with chronic genotype 1 HCV infection. Participants receive 12 weeks of treatment and continue assessments during a 24-week posttreatment follow-up period.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01938430 -
Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
|
Phase 2 | |
Completed |
NCT01984294 -
Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection
|
Phase 2 | |
Completed |
NCT02074514 -
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
|
Phase 3 | |
Recruiting |
NCT05395416 -
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C
|
Phase 2/Phase 3 | |
Completed |
NCT03458481 -
Phase 2 Study of Yimitasvir Phosphate Capsules
|
Phase 2 | |
Completed |
NCT02010255 -
Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
|
Phase 2 | |
Recruiting |
NCT00842205 -
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
|
N/A | |
Completed |
NCT02973503 -
Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
|
Phase 3 | |
Recruiting |
NCT03540212 -
Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus
|
Phase 2/Phase 3 | |
Completed |
NCT02021656 -
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection
|
Phase 3 | |
Completed |
NCT02021643 -
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
|
Phase 3 | |
Completed |
NCT02120300 -
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
|
Phase 2 | |
Completed |
NCT03487107 -
Phase 3 Study of Yimitasvir Phosphate Capsules
|
Phase 3 |